Research
Hormonal
The study highlights a persistently elevated pulmonary aspiration risk in patients receiving semaglutide.
Anesthesiologists should be cautious of the increased aspiration risk in patients on semaglutide during surgery.
StrongSupportsmedium confidence
Our findings highlight a persistently elevated pulmonary aspiration risk, even after withholding one administration of semaglutide.
Why this rating
Based on a prospective, multicentre, matched case-control study design.
Source
Gastric ultrasound in patients receiving semaglutide: a prospective, multicentre, matched control study
Nils Vlaeminck et al. · Anaesthesia · 2026
DOI 10.1111/anae.70129
cohort · n=88Cited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →